| Q34987693 | (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer |
| Q36502692 | (18)F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer |
| Q37827752 | A new dimension of FDG-PET interpretation: assessment of tumor biology. |
| Q35256725 | Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer |
| Q33945133 | Challenges in clinical prostate cancer: role of imaging |
| Q40011076 | Characterization of osteolytic, osteoblastic, and mixed lesions in a prostate cancer mouse model using 18F-FDG and 18F-fluoride PET/CT |
| Q39874026 | Characterization of preclinical models of prostate cancer using PET-based molecular imaging |
| Q53240780 | Clinical implication of FDG-PET in advanced gastric cancer with signet ring cell histology. |
| Q39512219 | Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines? |
| Q37137623 | Emerging metabolic targets in the therapy of hematological malignancies |
| Q53192471 | Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT. |
| Q37352995 | FDG PET in Prostate Cancer |
| Q35332601 | FDG-PET parameters as prognostic factor in esophageal cancer patients: a review |
| Q44983243 | Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions |
| Q34035683 | Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations |
| Q36834536 | Imaging in genitourinary cancer from the urologists' perspective |
| Q36469177 | Imaging localized prostate cancer: current approaches and new developments. |
| Q98226346 | Incidentally Detected 18F-FDG-Avid Prostate Cancer Diagnosed Using a Novel Fusion Biopsy Platform |
| Q39003083 | Is There Use for FDG-PET in Prostate Cancer? |
| Q37325974 | Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. |
| Q36129937 | Molecular imaging of prostate cancer: PET radiotracers |
| Q37390670 | PET of Glucose Metabolism and Cellular Proliferation in Prostate Cancer |
| Q36085426 | PET/CT Imaging and Radioimmunotherapy of Prostate Cancer |
| Q36308766 | PET/CT in prostate cancer: non-choline radiopharmaceuticals |
| Q36462108 | Positron emission tomography and molecular imaging of the prostate: an update. |
| Q33625371 | Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer |
| Q36448703 | Positron emission tomography: clinical applications in oncology. Part 2. |
| Q35244433 | Prognostic Utility of PET in Prostate Cancer. |
| Q36279410 | Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma |
| Q34448553 | Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline |
| Q34235986 | Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET |
| Q92157136 | Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223 |
| Q37725130 | The clinical advances of fluorine-2-D-deoxyglucose--positron emission tomography/computed tomography in urological cancers |
| Q90628323 | Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohor |
| Q35341169 | Tuberculous scar tumour detected by dual tracer positron emission-computerised tomography in a tuberculous endemic area. |
| Q27026828 | Update on positron emission tomography for imaging of prostate cancer |
| Q53482904 | [2006 technology monitoring report: clinical practice guideline: use of FDG-PET in kidney, prostate, testis and bladder cancers]. |
| Q37085677 | [F-18]-fluorodeoxyglucose PET-CT of the normal prostate gland |